Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faron Pharmaceuticals Oy ( (GB:FARN) ) just unveiled an announcement.
Faron Pharmaceuticals Ltd has approved the conversion of 352,989 special rights into new shares, valued at EUR 907,499.42, as part of the amortisation of its First Tranche Bonds. This decision is part of a broader convertible bond arrangement with Heights Capital Management, allowing the company to manage its debt by converting it into equity. The new shares will be registered and traded on Nasdaq First North Growth Market Finland and AIM, enhancing Faron’s financial flexibility and market presence.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to combat cancer. Their primary product, bexmarilimab, is an anti-Clever-1 humanized antibody aimed at reprogramming myeloid cell function to remove cancer immunosuppression. It is currently in Phase I/II clinical trials for treating hematological cancers.
Find detailed analytics on FARN stock on TipRanks’ Stock Analysis page.